| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019192363 |
| P356 | DOI | 10.1186/AR3071 |
| P8608 | Fatcat ID | release_thla3tsuyfce5ai2bozgthizaa |
| P932 | PMC publication ID | 2945023 |
| P698 | PubMed publication ID | 20609223 |
| P5875 | ResearchGate publication ID | 45100151 |
| P50 | author | Ken-ei Sada | Q51817163 |
| P2093 | author name string | Junko Inagaki | |
| Yoshifumi Ninomiya | |||
| Hirofumi Makino | |||
| Hiroko Ogawa | |||
| Satoshi Hirohata | |||
| Keiichiro Nishida | |||
| Tomoko Kawabata | |||
| Yasutaka Kadota | |||
| Koji Takasugi | |||
| P2860 | cites work | Translating the Histone Code | Q22065840 |
| Histone deacetylases specifically down-regulate p53-dependent gene activation | Q22253949 | ||
| MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation | Q24537700 | ||
| Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis | Q57081069 | ||
| Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis | Q73628334 | ||
| Rheumatoid arthritis market | Q81360046 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Roles of histone acetyltransferases and deacetylases in gene regulation | Q28286019 | ||
| Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase 1. | Q33278013 | ||
| Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms | Q33341474 | ||
| The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines | Q34015778 | ||
| Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression | Q34088777 | ||
| Regional analysis of p53 mutations in rheumatoid arthritis synovium | Q34098828 | ||
| Effects of sodium butyrate, a new pharmacological agent, on cells in culture | Q34249353 | ||
| Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? | Q34393807 | ||
| The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo | Q34504770 | ||
| Deacetylase enzymes: biological functions and the use of small-molecule inhibitors | Q34528043 | ||
| Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. | Q34837305 | ||
| Role for histone deacetylase 1 in human tumor cell proliferation | Q35948150 | ||
| Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. | Q36052572 | ||
| Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. | Q36600496 | ||
| Epigenetics in inflammatory rheumatic diseases | Q36985127 | ||
| ADAMTS1 is a unique hypoxic early response gene expressed by endothelial cells | Q37269167 | ||
| Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? | Q37317209 | ||
| Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. | Q38326758 | ||
| Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients | Q40229057 | ||
| Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation | Q40278633 | ||
| Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction. | Q40476125 | ||
| Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway | Q40497341 | ||
| Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity | Q40778493 | ||
| Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. | Q40857486 | ||
| Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation | Q41140580 | ||
| Transcript profiling in Arabidopsis reveals complex responses to global inhibition of DNA methylation and histone deacetylation | Q42163857 | ||
| Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis | Q43979359 | ||
| Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial | Q44364956 | ||
| Histone acetylation-mediated regulation of genes in leukaemic cells. | Q44433169 | ||
| A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis | Q44643741 | ||
| Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. | Q44874861 | ||
| Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression | Q45099932 | ||
| Detection of the p53 regulator murine double-minute protein 2 in rheumatoid arthritis. | Q45293497 | ||
| Hyaluronan receptors involved in cytokine induction in monocytes | Q46317357 | ||
| Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma | Q46455509 | ||
| Histone deacetylases, HDAC1 and HSIR2, act as a negative regulator of ageing through p53 in human gingival fibroblast | Q47639011 | ||
| Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. | Q47830017 | ||
| Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. | Q53389033 | ||
| Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. | Q53588080 | ||
| ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. | Q54664599 | ||
| P433 | issue | 4 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | R133 | |
| P577 | publication date | 2010-07-07 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis | |
| P478 | volume | 12 |
| Q42572005 | (1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis |
| Q53662447 | A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model. |
| Q52333566 | Activation of Class I histone deacetylases contributes to mitochondrial dysfunction in cardiomyocytes with altered complex activities. |
| Q36257320 | Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve? |
| Q54161049 | Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue. |
| Q36706491 | Effects of Wutou Decoction on DNA Methylation and Histone Modifications in Rats with Collagen-Induced Arthritis. |
| Q35175427 | Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension |
| Q93147580 | Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis |
| Q91670951 | Epigenetic Regulation in the Pathogenesis of Sjögren Syndrome and Rheumatoid Arthritis |
| Q39189613 | Epigenetic alterations in rheumatoid arthritis fibroblast-like synoviocytes |
| Q26849371 | Epigenetic contributions in the development of rheumatoid arthritis |
| Q41991798 | Epigenetic regulation in bacterial infections: targeting histone deacetylases |
| Q38297582 | Epigenetic roots of immunologic disease and new methods for examining chromatin regulatory pathways |
| Q38210478 | Epigenetic-based immune intervention for rheumatic diseases |
| Q38145001 | Epigenetics in rheumatoid arthritis: a primer for rheumatologists |
| Q39190505 | Epigenetics in the pathogenesis of RA. |
| Q45967099 | Epigenetics of inflammatory arthritis. |
| Q37962605 | Epigenomic deregulation in the immune system. |
| Q87955785 | Genetic and epigenetic influences on the loss of tolerance in autoimmunity |
| Q38529234 | Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis |
| Q39446770 | Genomics and epigenomics in rheumatic diseases: what do they provide in terms of diagnosis and disease management? |
| Q28828435 | Guizhi-Shaoyao-Zhimu decoction attenuates rheumatoid arthritis partially by reversing inflammation-immune system imbalance |
| Q37838731 | HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis |
| Q41119263 | Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis. |
| Q37604525 | Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes |
| Q42730771 | Histone deacetylase inhibitors and periodontal bone loss. |
| Q38008692 | Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases. |
| Q54806462 | Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients |
| Q42345703 | Histone deacetylases in RA: epigenetics and epiphenomena. |
| Q42688359 | Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid |
| Q34988095 | Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production |
| Q37679886 | Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression |
| Q57080806 | Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis |
| Q42742359 | Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis |
| Q37155203 | Largazole, a class I histone deacetylase inhibitor, enhances TNF-α-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts |
| Q33982509 | MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts |
| Q37959304 | Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer |
| Q33654202 | Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009 |
| Q35593214 | Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain |
| Q58585469 | Reduced Activity of HDAC3 and Increased Acetylation of Histones H3 in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis |
| Q36742102 | Regulated transcription of human matrix metalloproteinase 13 (MMP13) and interleukin-1β (IL1B) genes in chondrocytes depends on methylation of specific proximal promoter CpG sites |
| Q64063293 | Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases |
| Q38936263 | Remote Burn Injury Increases Pulmonary Histone Deacetylase 1 and Reduces Histone Acetylation |
| Q94562756 | Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes |
| Q38264859 | Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases |
| Q33555281 | Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging |
| Q36369284 | Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? |
| Q38932108 | Role of epigenetics in modulation of immune response at the junction of host-pathogen interaction and danger molecule signaling |
| Q36190823 | Skeletal Muscle Loss is Associated with TNF Mediated Insufficient Skeletal Myogenic Activation After Burn |
| Q84543679 | Some applications of pharmacogenomics and epigenetics in drug development and use in pursuit of personalized medicine |
| Q42145272 | Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change |
| Q39105700 | The Histone Modification Code in the Pathogenesis of Autoimmune Diseases |
| Q37578673 | The Mechanisms Underlying Chronic Inflammation in Rheumatoid Arthritis from the Perspective of the Epigenetic Landscape. |
| Q47233649 | The Tumor-like Phenotype of Rheumatoid Synovium: Molecular Profiling and Prospects for Precision Medicine |
| Q39094945 | The acetyl code in rheumatoid arthritis and other rheumatic diseases |
| Q86201191 | The ascent of acetylation in the epigenetics of rheumatoid arthritis |
| Q64099722 | The emerging role of epigenetics in human autoimmune disorders |
| Q37702568 | The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation |
| Q38108667 | The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes |
| Q38063961 | The role of stromal cells in the persistence of chronic inflammation |
| Q87824606 | [Synovial fibroblasts : Main players in rheumatoid arthritis] |
Search more.